Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Down syndrome (DS) is the main genetic cause of intellectual disability worldwide. The overexpression of the Amyloid Precursor Protein, present in chromosome 21, leads to β‐amyloid deposition that results in Alzheimer disease (AD) and, in most cases, also to cerebral amyloid angiopathy (CAA) neuropathology. People with DS invariably develop the neuropathological hallmarks of AD at the age of 40, and they are at an ultra high risk for suffering AD‐related cognitive impairment thereafter. In the general population, cerebrovascular disease is a significant contributor to AD‐related cognitive impairment, while in DS remains understudied. This review describes the current knowledge on cerebrovascular disease in DS and reviews the potential biomarkers that could be useful in the future studies, focusing on CAA. We also discuss available evidence on sporadic AD or other genetically determined forms of AD. We highlight the urgent need of large biomarker‐characterized cohorts, including neuropathological correlations, to study the exact contribution of CAA and related vascular factors that play a role in cognition and occur with aging, their characterization and interrelationships. DS represents a unique context in which to perform these studies as this population is relatively protected from some conventional vascular risk factors and they develop significant CAA, DS represents a particular atheroma‐free model to study AD‐related vascular pathologies. Only deepening on these underlying mechanisms, new preventive and therapeutic strategies could be designed to improve the quality of life of this population and their caregivers and lead to new avenues of treatment also in the general AD population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“In sporadic AD, however, an increased and altered production together with a reduced clearance of Aß could be the main mechanisms involved (Mawuenyega et al., 2010; Pera et al., 2013) (Figure 2).”
BackgroundClearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Matthews, K. A., Xu, W., Gaglioti, A. H., Holt, J. B., Croft, J. B., Mack, D., & McGuire, L. C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3063 · Cited by 1,124
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy
Linn, J., Halpin, A., Demaerel, P., Ruhland, J., Giese, A. D., Dichgans, M., van Buchem, M. A., Bruckmann, H., & Greenberg, S. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dad605 · Cited by 914 · cited 1×
“The diagnosis of possible or probable CAA in vivo is made based on clinico‐radiological features that are collected within the modified Boston criteria (Linn et al., 2010) (Table 1).”
MethodApolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857 · cited 2×
“Variation in APOE gene is the best established genetic risk factor for sporadic CAA (Verghese et al., 2011), APOE‐ε2 and APOE‐ε4 alleles are both associated with more severe CAA and increase the risk of sporadic”
BackgroundImpact of multiple pathologies on the threshold for clinically overt dementia
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1717-7 · Cited by 739
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711 · cited 2×
“disease is a wide critical comorbidity that accelerates the age of onset of clinical symptoms of AD, lowers the threshold for dementia for a given AD pathology burden and leads to a faster progression of the disease (Kapasi, DeCarli, & Schneider, 2017; Sweeney et al., 2019).”
BackgroundCerebral amyloid angiopathy in the elderly
Viswanathan, A., & Greenberg, S. M. (2011) · Annals of Neurology · doi:10.1002/ana.22516 · Cited by 643 · cited 1×
“Aß1‐40, in addition, is the major form of Aß deposited in the vessel walls in individuals with CAA (Viswanathan et al., 2011).”
BackgroundCharidimou, A., Gang, Q., & Werring, D. J. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301308 · Cited by 611
Vascular contributions to cognitive impairment and dementia including Alzheimer's disease
Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., Lamb, B. T., Montine, T. J., Nedergaard, M., Schaffer, C. B., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.008 · Cited by 603 · cited 1×
“Most cases of dementia in older adults have evidence of AD pathology and cerebrovascular disease (Arvanitakis, Capuano, Leurgans, Bennett, & Schneider, 2016; Snyder et al., 2015) and even both diseases could even share common genetic factors in some individuals (Broce et al.”
BackgroundLemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 2×
“Some subjects with DS start to accumulate Aβ in their brain in childhood and adolescence (Lemere et al., 1996), and most of the individuals will have accumulated substantial amounts of diffuse plaques of Aβ by the age of 20 (Davidson, Robinson, Prasher, & Mann, 2018).”
BackgroundArvanitakis, Z., Capuano, A. W., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30029-1 · Cited by 581
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · cited 12×
“Pathophysiologically, from a simplistic point of view, a chronic increase in the absolute or relative production of Aβ1‐42 over time could be the prevailing mechanism in ADAD (Bateman et al., 2011).”
BackgroundInfluentialA genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562 · cited 2×
“DS is one of the strongest single genetic risk factors for AD (Wiseman et al., 2015).”
BackgroundKalaria, R. N. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1571-z · Cited by 441 · cited 2×
“The presence of cerebrovascular pathology may be a critical comorbidity that anticipates the age of onset of dementia and leads to faster disease progression (Kalaria, 2016).”
BackgroundClinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417
Charidimou, A., Linn, J., Vernooij, M. W., Opherk, C., Akoudad, S., Baron, J.-C., Greenberg, S. M., Jäger, H. R., & Werring, D. J. (2015) · Brain · doi:10.1093/brain/awv162 · Cited by 385
Thal, D. R., Ghebremedhin, E., Orantes, M., & Wiestler, O. D. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.12.1287 · Cited by 384
Cerebral amyloid angiopathy pathology and cognitive domains in older persons
Arvanitakis, Z., Leurgans, S. E., Wang, Z., Wilson, R. S., Bennett, D. A., & Schneider, J. A. (2011) · Annals of Neurology · doi:10.1002/ana.22112 · Cited by 383 · cited 1×
“Previous studies have reported, as markers of cognitive decline, a worse perceptual speed and episodic memory in individuals with moderate‐to‐severe CAA abnormalities at autopsy than those with none‐to‐minimum CAA, independent of AD pathology, cerebral infarcts, Lewy bodies, age at death, sex, and education (Arvanitak…”
BackgroundCerebral amyloid angiopathy and its relationship to Alzheimer’s disease
Thal, D. R., Griffin, W. S. T., de Vos, R. A. I., & Ghebremedhin, E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0366-2 · Cited by 372
Course of cerebral amyloid angiopathy–related inflammation
Kinnecom, C., Lev, M. H., Wendell, L., Smith, E. E., Rosand, J., Frosch, M. P., & Greenberg, S. M. (2007) · Neurology · doi:10.1212/01.wnl.0000260066.98681.2e · Cited by 333 · cited 2×
“to a clinico‐radiological response (Carmona‐Iragui et al., 2015; Kinnecom et al., 2007).”
BackgroundA prospective 20‐year longitudinal follow‐up of dementia in persons with Down syndrome
McCarron, M., McCallion, P., Reilly, E., Dunne, P., Carroll, R., & Mulryan, N. (2017) · Journal of Intellectual Disability Research · doi:10.1111/jir.12390 · Cited by 295
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289
Association of apolipoprotein E ϵ2 and vasculopathy in cerebral amyloid angiopathy
Greenberg, S. M., Vonsattel, J.-P. G., Segal, A. Z., Chiu, R. I., Clatworthy, A. E., Liao, A., Hyman, B. T., & Rebeck, G. W. (1998) · Neurology · doi:10.1212/wnl.50.4.961 · Cited by 267
Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP
Doran, E., Keator, D., Head, E., Phelan, M. J., Kim, R., Totoiu, M., Barrio, J. R., Small, G. W., Potkin, S. G., & Lott, I. T. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160836 · Cited by 244 · cited 3×
“Authors suggest that those findings confirm the obligatory role of APP in the clinical, biochemical and neuropathological findings of AD in DS (Doran et al., 2017).”
BackgroundSedentary behavior: Understanding and influencing adults' prolonged sitting time
Owen, N. (2012) · Preventive Medicine · doi:10.1016/j.ypmed.2012.08.024 · Cited by 187 · cited 1×
“In the general population, sedentary behavior is associated with poor health outcomes, such as metabolic syndrome, glucose abnormalities, and premature cardiovascular mortality (Owen, 2012).”
BackgroundStructural network alterations and neurological dysfunction in cerebral amyloid angiopathy
Reijmer, Y. D., Fotiadis, P., Martinez-Ramirez, S., Salat, D. H., Schultz, A., Shoamanesh, A., Ayres, A. M., Vashkevich, A., Rosas, D., Schwab, K., et al. (2015) · Brain · doi:10.1093/brain/awu316 · Cited by 181
Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
Hithersay, R., Startin, C. M., Hamburg, S., Mok, K. Y., Hardy, J., Fisher, E. M. C., Tybulewicz, V. L. J., Nizetic, D., & Strydom, A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3616 · Cited by 176
Microinfarcts, brain atrophy, and cognitive function: The Honolulu Asia Aging Study Autopsy Study
Launer, L. J., Hughes, T. M., & White, L. R. (2011) · Annals of Neurology · doi:10.1002/ana.22520 · Cited by 171
Topography of dilated perivascular spaces in subjects from a memory clinic cohort
Martinez-Ramirez, S., Pontes-Neto, O. M., Dumas, A. P., Auriel, E., Halpin, A., Quimby, M., Gurol, M. E., Greenberg, S. M., & Viswanathan, A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828f1876 · Cited by 163 · cited 1×
“• Dilated perivascular spaces: Their presence in centrum semiovale is associated with the number of lobar microbleeds and cSS (Martinez‐Ramirez et al., 2013).”
BackgroundCortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy
Charidimou, A., Peeters, A. P., Jäger, R., Fox, Z., Vandermeeren, Y., Laloux, P., Baron, J.-C., & Werring, D. J. (2013) · Neurology · doi:10.1212/01.wnl.0000435298.80023.7a · Cited by 155
Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer’s disease
Broce, I. J., Tan, C. H., Fan, C. C., Jansen, I., Savage, J. E., Witoelar, A., Wen, N., Hess, C. P., Dillon, W. P., Glastonbury, C. M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1928-6 · Cited by 140 · cited 2×
“, 2015) and even both diseases could even share common genetic factors in some individuals (Broce et al., 2018).”
BackgroundTrisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP
Wiseman, F. K., Pulford, L. J., Barkus, C., Liao, F., Portelius, E., Webb, R., Chávez-Gutiérrez, L., Cleverley, K., Noy, S., Sheppard, O., et al. (2018) · Brain · doi:10.1093/brain/awy159 · Cited by 133 · cited 3×
“This finding suggesting that other still unidentified genes, not only APP, do also play a role on the development of AD in DS (Wiseman et al., 2018).”
BackgroundInfluentialCortical atrophy in patients with cerebral amyloid angiopathy: a case-control study
Fotiadis, P., van Rooden, S., van der Grond, J., Schultz, A., Martinez-Ramirez, S., Auriel, E., Reijmer, Y., van Opstal, A. M., Ayres, A., Schwab, K. M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30030-8 · Cited by 124
Cerebrovascular pathology in Down syndrome and Alzheimer disease
Head, E., Phelan, M. J., Doran, E., Kim, R. C., Poon, W. W., Schmitt, F. A., & Lott, I. T. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0499-4 · Cited by 105 · cited 5×
“In DS, in coherence with previous clinical reports, atherosclerosis and arteriolosclerosis vascular pathology has found to be uncommon in DS (Head et al., 2017).”
BackgroundResultInfluentialRingman, J. M., Monsell, S., Ng, D. W., Zhou, Y., Nguyen, A., Coppola, G., Van Berlo, V., Mendez, M. F., Tung, S., Weintraub, S., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv028 · Cited by 99 · cited 3×
“Despite the different genetic background, the AD neuropathological findings in sporadic AD, ADAD, and DS are very similar (Duyckaerts, Uchihara, Seilhean, He, & Hauw, 1997; Ringman et al., 2016), however, cerebrovascular disease and CAA findings presence and contribution could differ between those forms of AD.”
BackgroundIulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
Mann, D. M. A., Davidson, Y. S., Robinson, A. C., Allen, N., Hashimoto, T., Richardson, A., Jones, M., Snowden, J. S., Pendleton, N., Potier, M.-C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1866-3 · Cited by 73 · cited 3×
“…cortex; type 3, characterized by capillary and arterial CAA, especially within primary visual cortex, but with relatively few Aß plaques; and type 4, a vascular phenotype, where Aß deposition is more prevalent 730 | CARMONA‐IRAGUI et Al. in vessels and Aß plaques are scarce (Mann et al., 2018).”
BackgroundInfluentialCerebrovascular contributions to aging and Alzheimer's disease in Down syndrome
Wilcock, D. M., Schmitt, F. A., & Head, E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.007 · Cited by 56
Cerebral β-Amyloid Angiopathy Is Associated with Earlier Dementia Onset in Alzheimer's Disease
Vidoni, E. D., Yeh, H.-W., Morris, J. K., Newell, K. L., Alqahtani, A., Burns, N. C., Burns, J. M., & Billinger, S. A. (2016) · Neurodegenerative Diseases · doi:10.1159/000441919 · Cited by 37 · cited 1×
“CAA is neuropathologically found in more than 85% of cases with sporadic AD and has been associated with an earlier dementia onset in AD (Vidoni et al., 2016) within the general population.”
Background
Cited by
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Self-citationFurther understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Self-citationWhite matter hyperintensities are associated with subthreshold amyloid accumulation
Moscoso, A., Rey-Bretal, D., Silva-Rodríguez, J., Aldrey, J. M., Cortés, J., Pías-Peleteiro, J., Ruibal, Á., & Aguiar, P. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116944 · Cited by 49
Sheline, Y. I., Snider, B. J., Beer, J. C., Seok, D., Fagan, A. M., Suckow, R. F., Lee, J.-M., Waligorska, T., Korecka, M., Aselcioglu, I., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010725 · Cited by 45
Metadata
- Authors
- Carmona‐Iragui, M., Videla, L., Lleó, A., & Fortea, J.
- Venue
- Developmental Neurobiology
- Publisher
- Wiley
- Published
- 2019-07
- Volume
- 79
- Issue
- 7
- Pages
- 716-737
- ISSN
- 1932-8451 (ISSN-L)
- 1932-846X
- OpenAlex
- W2954901910
- Cited by
- 65
- References
- 42
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.